All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Philippe Armand and Roch Houot share information related to the recently launched COVID-HEME initiative including how hematologists can get involved.
COVID-HEME is a peer-to-peer forum for physicians about the care of patients with hematologic malignancies during the COVID-19 pandemic. The goal of this collaborative platform is to improve and accelerate the knowledge and experience of physicians to optimize the management of patients during the pandemic.
To join COVID-HEME, please ask for an invitation at covid.heme@gmail.com
COVID-HEME forum supports hematologists during COVID-19 pandemic
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox